Effect of Sleep Deprivation on Breathlessness and Exercise Capacity in COPD
NCT ID: NCT04997200
Last Updated: 2025-05-21
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
NA
Total Enrollment
20 participants
Study Classification
INTERVENTIONAL
Study Start Date
2021-09-13
Study Completion Date
2024-10-24
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This is a randomized controlled cross-over trial designed to measure the effect of one night's sleep deprivation on exercise endurance, ventilation and breathlessness in outpatients with COPD.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Sleep Deprivation on Diaphragm Command During an Inspiratory Endurance Trial in Healthy Volunteers.
NCT02725190
Sleep Deprivation
Healthy Volunteers
Diaphragm
COMPLETED
NA
The Effects of Sleep Deprivation on Physiological and Perceptual Responses During Exercise
NCT05313932
Sleep Deprivation
UNKNOWN
NA
Randomized Controlled Trial of a Self-help Book for Insomnia in Patients With Co-morbid OSA and Insomnia
NCT02279056
Sleep Apnea
Insomnia
COMPLETED
NA
Predictors of the Metabolic Effect of Sleep Loss
NCT00965783
Apnea
Obstructive Sleep Apnea (OSA)
Obesity
COMPLETED
NA
Aerobic Exercise: A Potential Rescue From the Negative Ramifications of Poor Sleep
NCT06956963
Cardiovascular Health
Sleep
RECRUITING
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Background:
Chronic Obstructive Pulmonary Disease (COPD) is a major cause of morbidity and mortality in the world. Breathlessness and exercise limitation are cardinal symptoms in COPD with grave consequences for the patient. Even with optimal COPD treatment a large number of these patients experience a breathlessness which limits their everyday life. Physical activity is the main trigger of breathlessness in daily life, but knowledge is limited on how other factors may affect exercise performance, breathing and exertional breathlessness in patients with COPD.
Sleep deprivation is common in the population in patients with COPD, and especially in patients with worsening health status and during hospitalizations. As many as 40-45% of patients older than 70 experience sleep deprivation during hospitalization. As many as 21 % of patients with COPD have a disturbed sleep. A recent study on healthy young males who breathed against an inspiratory resistance showed that one night's sleep deprivation significantly reduced their respiratory endurance and induced worse and more disturbing breathlessness.
Little is known how sleep loss affects patients with COPD in an outpatient setting. Several studies have evaluated the effect of sleep deprivation on exercise capacity in young healthy adults. However, very few studies have examined the effect of sleep deprivation on the exercise capacity or exertional breathlessness in patients with COPD; most data pertain to observational studies where no intervention took place and data from a randomized controlled trial (RCT) is needed. The presence of disturbed sleep in patients with COPD - and especially in relation to worsenings and hospitalizations, could have a marked detrimental effect on their breathing, increase suffering from distressing breathlessness and potentially increase the risk of adverse health outcomes and worse prognosis. Directed actions to improve sleeping in these settings could in that case improve the patients' outcomes.
Aim:
To test the effect of one sleepless night on breathlessness, exercise endurance and ventilation in patients with COPD.
Method:
This is a randomized (ratio 1:1), controlled, crossover trial of the effect of one night's sleep deprivation vs. normal sleep on exercise endurance, ventilation and breathlessness in outpatients with COPD. The study will not be blinded for participants and staff (due to the nature of the intervention) but will be blinded for the analyst.
The intervention is one night without sleep, and the control is one night with normal sleep. The test is a bicycle test (exercise test on a bike with continuous analysis of ventilation and gaseous exchange) carried out as a sub-max test at 75% of maximum capacity until the test person cannot go on.
The study consists of three visits. At the first visit, informed consent is collected, and inclusion and exclusion criteria are evaluated. Also, information is collected regarding the person's COPD-diagnosis, medication, and other illnesses. Specific surveys are Pittsburgh Sleep Quality Index (PSQI), COPD Assessment Test (CAT), modified Medical Research Council (mMRC) scale, 7-point Global Impression of Change (GIC) scale, Experienced sleep quality (Likert scale), Multidimensional Dyspnea Profile (MDP) to assess the person's sleep and respiration. Baseline values for dynamic spirometry, saturation, and blood pressure are also measured during the first visit. Afterwards, a bicycle test is carried out according to normal clinical standards. This involves increasing the resistance (in Watts) according to a set protocol until the test person is unable to continue. This takes roughly 6-10 minutes and provides a maximum performance value for the individual. This maximum value is used for visit number two and three. After this first visit the order of the sleepless night is randomized for either visit two or three.
At the second and third visit spirometry, saturation and blood pressure are once more measured. The person is evaluated for contraindications. Then a new bicycle test is carried out at 75% of the maximum W achieved at the first visit. The test takes around 10 minutes, and continues until the person is unable to continue. During this test, ventilation is measured as respiratory rate (RR), minute ventilation (MV), oxygen consumption (VO2), carbon dioxide consumption (VCO2), the respiratory quotient (VCO2/VO2), inspiratory capacity manoeuvre (IC), dynamic hyperinflation, ventilatory reserve capacity, ventilation efficiency (MV/VCO2-curve) and the anaerobic threshold. During the test the person is also assessed for how difficult the breathing feels (0-19 Borg CR10), how tired the legs feels (Borg CR10), how uncomfortable the breathing feels (mBorg 0-10) every two minutes and at the end of the test. At the end of the test the test person is asked about the reason for ending the test, how the breathing was experienced (Multidimensional Dyspnea Profile, MDP), and how motivated they were to carry out the test (0-10 NRS). The person is also monitored with EKG during the test, and the blood pressure is measured every two minutes. The results are then compared between the test where the person had a normal night's sleep, and the test where the person was awake the whole night before.
The normal night's sleep is assessed using some simple questions, such as: "How did you sleep tonight" and "How satisfied are you with the night's sleep?". It is also evaluated using an Actigraph bracelet that measures movement when worn. The bracelet is worn for 48 hours preceding both tests.
The night when the person is going to be awake is spent at the test lab, after eating a normal dinner at home. They then spend an entire night in a room where they can watch TV, use a phone or tablet or read books and magazines. They will be monitored by staff to help them stay awake during the night. They cannot eat, drink or smoke anything not usually consumed during the night (other than water). They then eat a normal breakfast of their choosing, and the test is carried out just like the one where they slept normally.
Chronic Obstructive Pulmonary Disease (COPD) is a major cause of morbidity and mortality in the world. Breathlessness and exercise limitation are cardinal symptoms in COPD with grave consequences for the patient. Even with optimal COPD treatment a large number of these patients experience a breathlessness which limits their everyday life. Physical activity is the main trigger of breathlessness in daily life, but knowledge is limited on how other factors may affect exercise performance, breathing and exertional breathlessness in patients with COPD.
Sleep deprivation is common in the population in patients with COPD, and especially in patients with worsening health status and during hospitalizations. As many as 40-45% of patients older than 70 experience sleep deprivation during hospitalization. As many as 21 % of patients with COPD have a disturbed sleep. A recent study on healthy young males who breathed against an inspiratory resistance showed that one night's sleep deprivation significantly reduced their respiratory endurance and induced worse and more disturbing breathlessness.
Little is known how sleep loss affects patients with COPD in an outpatient setting. Several studies have evaluated the effect of sleep deprivation on exercise capacity in young healthy adults. However, very few studies have examined the effect of sleep deprivation on the exercise capacity or exertional breathlessness in patients with COPD; most data pertain to observational studies where no intervention took place and data from a randomized controlled trial (RCT) is needed. The presence of disturbed sleep in patients with COPD - and especially in relation to worsenings and hospitalizations, could have a marked detrimental effect on their breathing, increase suffering from distressing breathlessness and potentially increase the risk of adverse health outcomes and worse prognosis. Directed actions to improve sleeping in these settings could in that case improve the patients' outcomes.
Aim:
To test the effect of one sleepless night on breathlessness, exercise endurance and ventilation in patients with COPD.
Method:
This is a randomized (ratio 1:1), controlled, crossover trial of the effect of one night's sleep deprivation vs. normal sleep on exercise endurance, ventilation and breathlessness in outpatients with COPD. The study will not be blinded for participants and staff (due to the nature of the intervention) but will be blinded for the analyst.
The intervention is one night without sleep, and the control is one night with normal sleep. The test is a bicycle test (exercise test on a bike with continuous analysis of ventilation and gaseous exchange) carried out as a sub-max test at 75% of maximum capacity until the test person cannot go on.
The study consists of three visits. At the first visit, informed consent is collected, and inclusion and exclusion criteria are evaluated. Also, information is collected regarding the person's COPD-diagnosis, medication, and other illnesses. Specific surveys are Pittsburgh Sleep Quality Index (PSQI), COPD Assessment Test (CAT), modified Medical Research Council (mMRC) scale, 7-point Global Impression of Change (GIC) scale, Experienced sleep quality (Likert scale), Multidimensional Dyspnea Profile (MDP) to assess the person's sleep and respiration. Baseline values for dynamic spirometry, saturation, and blood pressure are also measured during the first visit. Afterwards, a bicycle test is carried out according to normal clinical standards. This involves increasing the resistance (in Watts) according to a set protocol until the test person is unable to continue. This takes roughly 6-10 minutes and provides a maximum performance value for the individual. This maximum value is used for visit number two and three. After this first visit the order of the sleepless night is randomized for either visit two or three.
At the second and third visit spirometry, saturation and blood pressure are once more measured. The person is evaluated for contraindications. Then a new bicycle test is carried out at 75% of the maximum W achieved at the first visit. The test takes around 10 minutes, and continues until the person is unable to continue. During this test, ventilation is measured as respiratory rate (RR), minute ventilation (MV), oxygen consumption (VO2), carbon dioxide consumption (VCO2), the respiratory quotient (VCO2/VO2), inspiratory capacity manoeuvre (IC), dynamic hyperinflation, ventilatory reserve capacity, ventilation efficiency (MV/VCO2-curve) and the anaerobic threshold. During the test the person is also assessed for how difficult the breathing feels (0-19 Borg CR10), how tired the legs feels (Borg CR10), how uncomfortable the breathing feels (mBorg 0-10) every two minutes and at the end of the test. At the end of the test the test person is asked about the reason for ending the test, how the breathing was experienced (Multidimensional Dyspnea Profile, MDP), and how motivated they were to carry out the test (0-10 NRS). The person is also monitored with EKG during the test, and the blood pressure is measured every two minutes. The results are then compared between the test where the person had a normal night's sleep, and the test where the person was awake the whole night before.
The normal night's sleep is assessed using some simple questions, such as: "How did you sleep tonight" and "How satisfied are you with the night's sleep?". It is also evaluated using an Actigraph bracelet that measures movement when worn. The bracelet is worn for 48 hours preceding both tests.
The night when the person is going to be awake is spent at the test lab, after eating a normal dinner at home. They then spend an entire night in a room where they can watch TV, use a phone or tablet or read books and magazines. They will be monitored by staff to help them stay awake during the night. They cannot eat, drink or smoke anything not usually consumed during the night (other than water). They then eat a normal breakfast of their choosing, and the test is carried out just like the one where they slept normally.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
COPD
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
CROSSOVER
Performed in randomized order on two separate days, at least seven days apart and no more than six weeks apart.
* Intervention: A night without sleep. No daytime sleeping the day before the test. Participants are observed by staff at the trial unit during the night before the test.
* Control: Normal night's sleep (at least six hours of sleep) in the patient's home.
The participants wear an actigraph during 48 hours before the test to ensure adherence to the allocated condition (sleep deprivation or control).
* Intervention: A night without sleep. No daytime sleeping the day before the test. Participants are observed by staff at the trial unit during the night before the test.
* Control: Normal night's sleep (at least six hours of sleep) in the patient's home.
The participants wear an actigraph during 48 hours before the test to ensure adherence to the allocated condition (sleep deprivation or control).
Primary Study Purpose
BASIC_SCIENCE
Blinding Strategy
NONE
The analyst analyzing the data will be blinded.
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intervention: One night's sleeplessness
A night without sleep. No daytime sleeping the day before the test. Participants are observed by staff at the trial unit during the night before the test.
Group Type
EXPERIMENTAL
One night's sleeplessness
Intervention Type
BEHAVIORAL
A night without sleep. No daytime sleeping the day before the test. Participants are observed by staff at the trial unit during the night before the test.
Control: One night's normal sleep
A normal night's sleep (at least six hours) in the patient's home.
Group Type
NO_INTERVENTION
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
One night's sleeplessness
A night without sleep. No daytime sleeping the day before the test. Participants are observed by staff at the trial unit during the night before the test.
Intervention Type
BEHAVIORAL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 18 years or older
* COPD diagnosed by physician in accordance with Global Initiative For Chronic Obstructive Lung Disease (GOLD) guidelines (GOLD 2021), with a spirometric ratio of the forced expired volume in one second (FEV1) / forced vital capacity (FVC) \< 0.7 and a FEV1 \< 80% of predicted post bronchodilator at baseline.
* Self-reported average sleep time of six hours or longer during a normal night.
* No regular treatment with sleep medication or anxiolytics.
* Able to cycle
* Able to talk and write Swedish well enough to participate in the study procedures, as judged by the Investigator.
* COPD diagnosed by physician in accordance with Global Initiative For Chronic Obstructive Lung Disease (GOLD) guidelines (GOLD 2021), with a spirometric ratio of the forced expired volume in one second (FEV1) / forced vital capacity (FVC) \< 0.7 and a FEV1 \< 80% of predicted post bronchodilator at baseline.
* Self-reported average sleep time of six hours or longer during a normal night.
* No regular treatment with sleep medication or anxiolytics.
* Able to cycle
* Able to talk and write Swedish well enough to participate in the study procedures, as judged by the Investigator.
Exclusion Criteria
* Resting peripheral oxygen saturation (SpO2) \< 92%
* Night shift worker
* Hospitalization or clinical instability during the last four weeks
* Treatment with supplementary oxygen at rest or during exercise
* Sleep disturbance, defined as a Pittsburgh Sleep Quality Index \>5 at baseline
* Contraindication to exercise testing in accordance with clinical practice guidelines (ATS/ACCP Statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med 2003; 167:211-277)
* Expected survival shorter than six months as judged by the Investigator.
* Night shift worker
* Hospitalization or clinical instability during the last four weeks
* Treatment with supplementary oxygen at rest or during exercise
* Sleep disturbance, defined as a Pittsburgh Sleep Quality Index \>5 at baseline
* Contraindication to exercise testing in accordance with clinical practice guidelines (ATS/ACCP Statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med 2003; 167:211-277)
* Expected survival shorter than six months as judged by the Investigator.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Blekinge County Council Hospital
OTHER
Sponsor Role
collaborator
Skane University Hospital
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Magnus Ekström
MD, PhD, Associate professor
Responsibility Role
PRINCIPAL_INVESTIGATOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Blekinge Tekniska Högskola (BTH)
Karlskrona, Blekinge County, Sweden
Site Status
Department of Clinical Physiology, Blekinge Hospital
Karlskrona, Blekinge County, Sweden
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Sweden
References
Explore related publications, articles, or registry entries linked to this study.
O'Donnell DE, Banzett RB, Carrieri-Kohlman V, Casaburi R, Davenport PW, Gandevia SC, Gelb AF, Mahler DA, Webb KA. Pathophysiology of dyspnea in chronic obstructive pulmonary disease: a roundtable. Proc Am Thorac Soc. 2007 May;4(2):145-68. doi: 10.1513/pats.200611-159CC.
Reference Type
BACKGROUND
Agusti A, Edwards LD, Celli B, Macnee W, Calverley PM, Mullerova H, Lomas DA, Wouters E, Bakke P, Rennard S, Crim C, Miller BE, Coxson HO, Yates JC, Tal-Singer R, Vestbo J; ECLIPSE Investigators. Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort. Eur Respir J. 2013 Sep;42(3):636-46. doi: 10.1183/09031936.00195212. Epub 2013 Jun 13.
Reference Type
BACKGROUND
Simon ST, Bausewein C, Schildmann E, Higginson IJ, Magnussen H, Scheve C, Ramsenthaler C. Episodic breathlessness in patients with advanced disease: a systematic review. J Pain Symptom Manage. 2013 Mar;45(3):561-78. doi: 10.1016/j.jpainsymman.2012.02.022. Epub 2012 Aug 24.
Reference Type
BACKGROUND
Dharmarajan K, Swami S, Gou RY, Jones RN, Inouye SK. Pathway from Delirium to Death: Potential In-Hospital Mediators of Excess Mortality. J Am Geriatr Soc. 2017 May;65(5):1026-1033. doi: 10.1111/jgs.14743. Epub 2016 Dec 30.
Reference Type
BACKGROUND
Rault C, Sangare A, Diaz V, Ragot S, Frat JP, Raux M, Similowski T, Robert R, Thille AW, Drouot X. Impact of Sleep Deprivation on Respiratory Motor Output and Endurance. A Physiological Study. Am J Respir Crit Care Med. 2020 Apr 15;201(8):976-983. doi: 10.1164/rccm.201904-0819OC.
Reference Type
BACKGROUND
Chen R, Tian JW, Zhou LQ, Chen X, Yan HY, Zeng B, Zhang MS. The relationship between sleep quality and functional exercise capacity in COPD. Clin Respir J. 2016 Jul;10(4):477-85. doi: 10.1111/crj.12249. Epub 2015 Jan 15.
Reference Type
BACKGROUND
Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med. 2010 Jun 1;152(11):726-32. doi: 10.7326/0003-4819-152-11-201006010-00232. Epub 2010 Mar 24.
Reference Type
BACKGROUND
Hedenstrom H, Malmberg P, Fridriksson HV. Reference values for lung function tests in men: regression equations with smoking variables. Ups J Med Sci. 1986;91(3):299-310. doi: 10.3109/03009738609178670.
Reference Type
BACKGROUND
Related Links
Access external resources that provide additional context or updates about the study.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Version 1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Effect of Total Sleep Deprivation on Vascular Function
NCT04535219
COMPLETED
NA
Effects of Mild Hypobaric Hypoxia on Sleep and Post-sleep Performance
NCT00498563
COMPLETED
NA
Exercise and Insomnia Study: The Effects of 1 Week of Exercise Training on Insomnia Severity
NCT04402021
COMPLETED
NA
Metabolic and Muscular Adaptations During Inactivity in 3 Days of Bed-rest
NCT03495128
COMPLETED
NA
The Effects of Acute Total Sleep Deprivation Versus Normal Sleep on Metabolism
NCT01800253
COMPLETED
NA
The Acute Effect of Aerobic Exercise on Sleep in Patients With Depression
NCT03673397
COMPLETED
NA
Effect of Sleep Extension in Prevention to Sleep Deprivation
NCT06928168
RECRUITING
NA
Neurobehavioral Effects of Partial Sleep Deprivation
NCT02128737
COMPLETED
NA
Cerebral Blood Flow and Ventilatory Responses During Sleep in Normoxia and Intermittent Hypoxia
NCT03255408
UNKNOWN
PHASE1/PHASE2
Sleeping Habits on Performance Following Sleep Deprivation
NCT05942664
COMPLETED
NA
Sleep Deprivation : Effects on Driving Performance and Central Fatigue
NCT01606020
COMPLETED
NA
Sleep Deprivation and Energy Balance
NCT01334788
COMPLETED
NA
A Behavioral Therapy for Insomnia Co-existing With COPD
NCT01973647
COMPLETED
NA
Breath Biomarkers for Sleep Loss and Circadian Timing
NCT03980340
TERMINATED
Recruitment Strategies Comparing Different Strategies in Sleep Apnea and Prediabetes
NCT03984058
COMPLETED
NA
The SAD Study - SLEEP, ANXIETY & DEPRESSION Study A Prospective Cohort Study
NCT01985347
UNKNOWN
NA
Internet-based Cognitive-behavioral Treatment for Insomnia in COPD Patients Undergoing Pulmonary Rehabilitation
NCT04700098
COMPLETED
NA
Impairment of Sleep and Pattern of Breathing Before and After Opioid Withdrawal in Comparison to Patients Without Opioid Withdrawal
NCT01540890
COMPLETED
Sleep and Maximal Fat Oxidation
NCT07015008
COMPLETED
NA
Sleep and Resistance Exercise
NCT06606626
COMPLETED
NA
Epidemiology of Sleep-Disordered Breathing in Adults
NCT00005557
ACTIVE_NOT_RECRUITING
Impact of Chronic Circadian Disruption vs. Chronic Sleep Restriction on Metabolism
NCT02171273
COMPLETED
NA
Effects of Mild Hypobaric Hypoxia on Oxygen Saturation During Sleep
NCT00659009
COMPLETED
NA
Metabolic and Cognitive Parameters Following Partial Sleep Deprivation
NCT01823263
UNKNOWN
NA